Shuttle Pharmaceuticals (NASDAQ:SHPH) Major Shareholder Buys $27,939.08 in Stock

Posted by James Conley on Jul 16th, 2026

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH – Get Free Report) major shareholder Financial Lp Hrt acquired 8,266 shares of the stock in a transaction dated Thursday, July 9th. The shares were purchased at an average price of $3.38 per share, for a total transaction of $27,939.08. Following the completion of the purchase, the insider directly owned 60,540 shares in the company, valued at $204,625.20. The trade was a 15.81% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Financial Lp Hrt also recently made the following trade(s):

On Friday, July 10th, Financial Lp Hrt acquired 731 shares of Shuttle Pharmaceuticals stock. The stock was acquired at an average cost of $3.11 per share, with a total value of $2,273.41.
On Wednesday, July 8th, Financial Lp Hrt sold 18,531 shares of Shuttle Pharmaceuticals stock. The shares were sold at an average price of $3.52, for a total value of $65,229.12.
On Tuesday, July 7th, Financial Lp Hrt sold 10,580 shares of Shuttle Pharmaceuticals stock. The stock was sold at an average price of $3.33, for a total transaction of $35,231.40.
On Monday, July 6th, Financial Lp Hrt sold 9,022 shares of Shuttle Pharmaceuticals stock. The stock was sold at an average price of $3.51, for a total transaction of $31,667.22.
On Thursday, July 2nd, Financial Lp Hrt purchased 7,851 shares of Shuttle Pharmaceuticals stock. The shares were purchased at an average cost of $3.54 per share, with a total value of $27,792.54.
On Wednesday, July 1st, Financial Lp Hrt bought 3,959 shares of Shuttle Pharmaceuticals stock. The shares were purchased at an average cost of $3.30 per share, with a total value of $13,064.70.
On Tuesday, June 30th, Financial Lp Hrt acquired 6,755 shares of Shuttle Pharmaceuticals stock. The shares were bought at an average price of $3.23 per share, for a total transaction of $21,818.65.
On Monday, June 29th, Financial Lp Hrt bought 25,836 shares of Shuttle Pharmaceuticals stock. The shares were bought at an average price of $3.44 per share, with a total value of $88,875.84.

Shuttle Pharmaceuticals Stock Down 12.3%

Shares of Shuttle Pharmaceuticals stock opened at $3.65 on Thursday. The company has a market capitalization of $2.34 million, a price-to-earnings ratio of -0.08 and a beta of 0.29. The firm’s 50-day moving average price is $4.71 and its two-hundred day moving average price is $9.78. Shuttle Pharmaceuticals Holdings, Inc. has a 12-month low of $2.71 and a 12-month high of $55.90.

Institutional Trading of Shuttle Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of SHPH. Connective Capital Management LLC acquired a new stake in shares of Shuttle Pharmaceuticals in the 3rd quarter worth about $357,000. Geode Capital Management LLC bought a new stake in shares of Shuttle Pharmaceuticals during the 4th quarter worth $26,000. Boothbay Fund Management LLC bought a new stake in Shuttle Pharmaceuticals in the fourth quarter worth about $37,000. Finally, Ikarian Capital LLC purchased a new position in Shuttle Pharmaceuticals in the fourth quarter valued at approximately $124,000. Institutional investors own 4.58% of the company’s stock.

Wall Street Analyst Weigh In

SHPH has been the topic of several research reports. Weiss Ratings raised shares of Shuttle Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a report on Tuesday, June 30th. Wall Street Zen raised Shuttle Pharmaceuticals to a “sell” rating in a research note on Saturday, July 4th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, Shuttle Pharmaceuticals currently has an average rating of “Sell”.

View Our Latest Research Report on SHPH

Shuttle Pharmaceuticals Company Profile

(Get Free Report)

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .